Skip to main content

Cencora vs McKesson: Revenue, Profit and Business Model

Cencora had $321.3B of annual revenue in FY2025. McKesson had $403.4B of annual revenue in FY2026.

Latest financial snapshot

Cencora

Latest annual revenue
$321.3B (FY2025)
Net income
Unavailable here
Net margin
—
Revenue growth
+9.1% a year, FY2016–FY2025

McKesson

Latest annual revenue
$403.4B (FY2026)
Net income
Unavailable here
Net margin
—
Revenue growth
+14.3% a year, FY2024–FY2026

Financial summary

Cencora

Cencora's revenue rose from $238.6 billion in FY2022 to $321.3 billion in FY2025, while FY2025 net income attributable to Cencora was about $1.55 billion, a net margin of roughly half a percent. Growth in fiscal 2026 has been driven by specialty products, GLP-1 volume and the newly consolidated OneOncology. In the third quarter ended June 30, 2026, revenue grew 5.1% to $84.8 billion, adjusted operating income rose 17% to $1.2 billion, adjusted diluted EPS rose 12% to $4.48, and the company repurchased $1 billion of stock. Management raised fiscal 2026 adjusted EPS guidance to $17.75-$17.95 and expects about $3 billion of adjusted free cash flow. Cencora is a massive global pharmaceutical sourcing and distribution services company, sustaining a market valuation typically over $40 billion.

McKesson

McKesson reported fiscal 2026 revenue of $403.4 billion, up 12%, operating cash flow of $6.2 billion, and free cash flow of $5.4 billion. North American Pharmaceutical produced $336.7 billion of revenue; Oncology & Multispecialty produced $48.4 billion; Prescription Technology Solutions produced $5.8 billion; and Medical-Surgical Solutions produced $11.5 billion. Revenue should be read alongside segment profit and cash flow because distribution and retail represented about 98% of consolidated revenue but operate on thin margins.

Revenue and profit by year

Cencora

Cencora revenue, net income, margin and growth by fiscal year
YearRevenueNet incomeMarginGrowthSource
FY2025$321.3B——+9.3%Source
FY2024$294B——+12.1%Source
FY2023$262.2B——+9.9%Source
FY2022$238.6B——+11.5%Source
FY2021$214B$1.5B0.7%+12.7%Source
FY2020$189.9B-$3.4B-1.8%+5.7%Source
FY2019$179.6B$855.4M0.5%+6.9%Source
FY2018$167.9B$1.7B1.0%+9.7%Source
FY2017$153.1B$364.5M0.2%+4.3%Source
FY2016$146.8B$1.4B1.0%—Source
Full Cencora financials

McKesson

McKesson revenue, net income, margin and growth by fiscal year
YearRevenueNet incomeMarginGrowthSource
FY2026$403.4B——+12.3%Source
FY2025$359.1B——+16.2%Source
FY2024$309B———Source
Full McKesson financials

Where the revenue comes from

Cencora

  • U.S. Healthcare SolutionsMajority

    Wholesale distribution of branded, specialty brand, generic, over-the-counter, home healthcare, and related products to pharmacies, hospitals, physicians, and alternate-care providers.

  • International Healthcare Solutions

    Large secondary platform

    Pharmaceutical wholesale, specialty logistics, commercialization, regulatory, and market-access services across international markets.

  • Specialty and Provider Services

    Strategic growth area

    Services for specialty providers, manufacturers, oncology and retina practices, cold-chain movement, commercialization support, and patient access.

McKesson

  • North American Pharmaceutical

    Large majority

    U.S. and Canadian drug wholesaling to retail, institutional and independent pharmacy customers, including Health Mart.

  • Oncology & Multispecialty

    Not separately estimated

    Specialty distribution plus practice-management and data services for oncology, retina and other specialty practices.

  • Prescription Technology Solutions

    Small share of revenue

    CoverMyMeds, Rx Savings Solutions and biopharma access and affordability programs; a higher-margin contributor to operating profit.

  • Medical-Surgical Solutions

    Single-digit share

    Medical supplies and logistics for physician offices, long-term care and alternate care sites; being separated as Wellverse.

Business model and strategy

Cencora

How it makes money

Cencora makes money on volume and services rather than markups alone. It buys medicines from manufacturers, holds them in a national network of distribution centers and delivers them, often overnight, to pharmacies, hospitals, clinics and physician offices. Revenue is enormous because the full drug price passes through its books, but adjusted gross margin is only around 4% (4.16% in the June 2026 quarter).

Growth strategy

Cencora calls its strategy pharmaceutical-centric. Since 2024 it has redeployed capital toward specialty care: it bought about 85% of Retina Consultants of America for roughly $4.6 billion (closed January 2025) and agreed in December 2025 to buy the majority of OneOncology it did not already own from TPG and others for about $3.6 billion (closed February 2026).

Competitive advantage

Cencora's advantage is scale that is hard to copy: a national distribution network built for temperature-sensitive and controlled products, purchasing power with manufacturers, and deep specialty relationships. It is the leading distributor to community oncology practices and, through Retina Consultants of America and OneOncology, now also manages physician networks that prescribe high-cost specialty drugs.

Cencora business model in full

McKesson

How it makes money

McKesson makes money primarily by purchasing and distributing pharmaceuticals and medical products to pharmacies, hospitals, health systems, and other providers. Distribution is a high-volume, thin-margin business, so purchasing terms, logistics efficiency, order accuracy, customer contracts, and working-capital management drive results.

Growth strategy

McKesson is concentrating capital on oncology, multispecialty care, and biopharma services, where provider relationships and specialty capabilities can grow faster than traditional wholesale distribution. It is also expanding prescription access and affordability services, completing its exit from Europe, and pursuing a separation of Medical-Surgical Solutions.

Competitive advantage

McKesson's advantage is the combination of distribution scale, regulated logistics, supplier and customer relationships, specialty capabilities, and nationwide infrastructure. Those assets are expensive and difficult to replicate, but large customers retain negotiating power and the core distribution model remains sensitive to small changes in pricing, product mix, and costs.

McKesson business model in full

Questions about Cencora vs McKesson

Which company has higher revenue — Cencora, Inc. or McKesson Corporation?

Cencora, Inc. had $321.3B (FY2025), while McKesson Corporation had $403.4B (FY2026). By latest annual revenue, McKesson Corporation is the larger business, with Cencora, Inc. showing a smaller revenue base. Note: these are from different fiscal years and are not a direct like-for-like comparison.

What is the market cap of Cencora, Inc. vs McKesson Corporation?

Cencora, Inc. has a market capitalisation of $59.0B. A public market cap figure for McKesson Corporation was not available (it may be privately held).

How does revenue per employee compare for Cencora, Inc. and McKesson Corporation?

Cencora, Inc. has $6.30M / employee in revenue per employee, while McKesson Corporation has $9.38M / employee. Headcounts may use different dates, so the ratio alone does not establish which business operates more efficiently.

How do Cencora, Inc. and McKesson Corporation make money?

Cencora, Inc. and McKesson Corporation generate revenue in fundamentally different ways. Cencora, Inc.: Cencora makes money on volume and services rather than markups alone. McKesson Corporation: McKesson makes money primarily by purchasing and distributing pharmaceuticals and medical products to pharmacies, hospitals, health systems, and other providers.

Is Cencora, Inc. bigger than McKesson Corporation?

By last reported revenue, McKesson Corporation ($403.4B (FY2026)) is the larger company compared to Cencora, Inc. ($321.3B (FY2025)). Revenue scale is one dimension of size — market capitalisation, employee count, and geographic reach are also relevant depending on the context.

Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the Cencora vs McKesson overview

Content is for informational purposes only. Not financial advice. Data sourced from SEC filings, annual reports, and public records. See our full disclaimer and methodology.